Zoledronic Acid Reduces Periodontal Disease in Osteoporosis Patients

By Reuters Staff

September 27, 2019

NEW YORK (Reuters Health) - Once-yearly zoledronic acid helps prevent symptomatic periodontal disease in osteoporosis patients, according to industry-funded research.

Osteoporosis is closely associated with periodontal disease and tooth loss, Dr. Akira Taguchi of Matsumoto Dental University in Nagano, Japan, and colleagues note in in Menopause, online August 19. Small randomized clinical trials suggest that bisphosphonates (BPs) may have beneficial effects on periodontal disease in patients with good oral hygiene, they add.

The third-generation BP zoledronic acid, given by intravenous infusion annually, reduces fracture risk in osteoporosis patients.

In the new study, Dr. Taguchi and colleagues randomized 665 osteoporosis patients with good oral health and one to four vertebral fractures to receive zoledronic acid or placebo once a year for two years. Patients received instruction on good oral hygiene at baseline and every three months.

There were 67 cases of oral adverse events in the control group versus 47 in the zoledronic acid group (20.2% vs. 14.1%, P=0.04).

Forty patients (12%) in the control group were diagnosed with periodontal disease, compared to 18 patients (5.4%) on zoledronic acid (P=0.002).

There was no significant difference between the two groups in tooth loss, which occurred in 7.2% of the zoledronic acid group (24 cases) and 10.8% of the control group (36 cases).

Patients assigned to zoledronic acid were more likely to smoke, the authors note. "More significant improvement of marginal periodontitis might be observed in the zoledronic acid group if smoking was to be similar between the groups at baseline," they write.

Asahi Kasei Pharma, which markets zoledronic acid as Reclast in Japan, funded the research. Dr. Taguchi and other study authors have received consulting fees from the company.

SOURCE: https://bit.ly/2l2rIAT

Menopause 2019.